FIGMD, Inc. Announces Launch of Clinical Data Registry Platform on Google Glass

CHICAGO--FIGMD, Inc. is excited to announce the launch of its Clinical Data Registry Platform on Google Glass. A first in the health care quality measurement space, FIGMD’s innovative approach enables Doctors and other health care providers across the country to leverage the power data at the point of care. Clinical Data Registries can now inform health care providers about best practices, quality measures, and other context sensitive information at the point of care - when the ability to impact the quality of care being delivered is extreme. Doctors are able to get real-time measure qualification, review discrete clinical data which supports better decision making, and report on the completion of quality action as they treat the patient. FIGMD formally launched this technology at the CMSS Registries Summit on May 8, 2014 in Chicago.

“We look forward to pushing the boundaries, thinking differently, and making the impossible possible. The best is yet to come!”

“The Google Glass technology and FIGMD’s innovative use of it enables Doctors to unobtrusively integrate technology and data-driven intelligence into the patient care experience. FIGMD is thrilled to be at the forefront of innovation and build solutions that enable our Registry clients to better impact the quality of patient care,” said Sanket Baralay, President & CEO of FIGMD. “We look forward to pushing the boundaries, thinking differently, and making the impossible possible. The best is yet to come!”

FIGMD, Inc. provides Clinical Data Registry (CDR), Analytics and Data Reporting solutions to Doctors, Medical Professional Associations, hospital systems and more. FIGMD’s technologies and solutions help organizations massively scale their CDR projects in a time- and cost-conservative manner. FIGMD’s offerings are used by thousands of doctors and other health care providers across all 50 states. Visit http://www.figmd.com to learn more.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.